No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
WLY240621C40000
- 0.35
- -0.15-30.00%
15min DelayClose Jun 20 16:00 ET
0.35High0.35Low
0.35Open0.50Pre Close2 Volume266 Open Interest40.00Strike Price70.00Turnover42.39%IV1.20%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.4575Delta0.3882Gamma113.91Leverage Ratio-0.2034Theta0.0007Rho52.12Eff Leverage0.0096Vega
Intraday
- 5D
- Daily
News
John Wiley & Sons-A(WLY.US) Director Sells US$397.64K in Common Stock
$John Wiley & Sons-A(WLY.US)$ Director Dobson David C sold 10,000 shares of common stock on Jun 17, 2024 at an average price of $39.764 for a total value of $397.64K.Source: Announcement What is state
John Wiley & Sons-A(WLY.US) Officer Sells US$297.74K in Common Stock
$John Wiley & Sons-A(WLY.US)$ Officer Van Tassell Christina sold 7,530 shares of common stock on Jun 18, 2024 at an average price of $39.54 for a total value of $297.74K.Source: Announcement What is s
Form 144 | John Wiley & Sons-A(WLY.US) Officer Proposes to Sell 297.74K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 18, $John Wiley & Sons-A(WLY.US)$、$John Wiley & Sons-B(WLYB.US)$ Officer Christina Van Tassell intends to sell 7,530 shares of its common stock on Jun 18, with a total mark
Avidity Biosciences And CleanSpark Were Among The 10 Biggest Mid-Cap Stock Gainers Last Week (June 9-June 15): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Avidity Biosciences, Inc. (NASDAQ:RNA) shares jumped 50.15% following the announcement that the Phase 1/2 tri
Earnings Update: Here's Why Analysts Just Lifted Their John Wiley & Sons, Inc. (NYSE:WLY) Price Target To US$53.00
John Wiley & Sons Up 15%, Insider Buyers Are Up 34%
Last week, John Wiley & Sons, Inc. (NYSE:WLY) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 15% last week, resulting in a US$290m incre
Comments
Mixed Q3 results for the company with a significant beat on revenue expectations but a miss on full-year revenue guidance and a fall in operating margin. Long-term performance indicates weak business quality.
John Wiley & Sons (NYSE:WLY) Surprises With Q3 Sales But Full-Year Sales Guidance Misses ExpectationsJohn Wiley & Sons' share price drop may not be due to its dividend or top line performance. Future earnings are crucial for shareholders. Despite a 21% market rise, shareholders are down 22% this year. Over five years, they've faced a 4% annual loss.
1
The stock seems fairly valued at the moment, but given the uncertainty from negative returns in the future, this could be the right time to de-risk your portfolio. The negative growth outlook increases the risk of holding the stock.
John Wiley & Sons' projected revenue decline might make its price-to-sales ratio unjustifiable. If financial performance worsens, current stock price might not hold. Shrinking revenues could negatively affect its future stock price.
John Wiley & Sons' lack of reinvestment suggests it won't become a multi-bagger stock. With stable returns on existing capital, growth isn't likely soon. Investors also seem pessimistic with a 16% stock decline in the last five years.
Read more